| Biomarker ID | 501 |
| PMID | 20028763 |
| Year | 2009 |
| Biomarker | Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP) [Floating] |
| Biomarker Basis | Expression Based |
| Biomolecule | DNA (Gene) |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Biochemical recurrence (within 1 year ) Vs No recurrence (24 months) |
| Type of Biomarker | Prognostic |
| Cohort | All patients had clinical stage pT3 or pT2C. 30 patients were selected who expreienced biochemical reccurance within 1 y of RP and/or had positive lymph nodes identified at the time of surgery. Controls were selcted (n=24) such that they remained disease free for 24 months. |
| Senstivity | 80% |
| Specificity | 50% |
| AUC | NA |
| Accuracy | 67% |
| Level Of Significance | NA |
| Method Used | Array comparative genomic hybridization. |
| Clinical | No |
| Remarks | 39 BAC-based markers of metastasis to assess recurrence risk in silico for high-risk radical prostatectomy cases. This set of biomarkers, the Genomic Evaluators of Metastatic Prostate Cancer (GEMCaP). |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |